Research output

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

Associated organisations

    Research areas

  • Non-small cell lung cancer, Tyrosine kinase inhibitor, QT interval, Disease flare, Drug monitoring, CELL LUNG-CANCER, 1ST-LINE TREATMENT, PHASE-3 TRIAL, OPEN-LABEL, GEFITINIB, ADENOCARCINOMA, DACOMITINIB, INHIBITOR, ERLOTINIB, INTERVAL
View graph of relations


Original languageEnglish
Pages (from-to)92-98
Number of pages7
JournalEuropean Journal of Cancer
Publication statusPublished - 1 Mar 2018